Antibody-drug conjugate developer Duality Biotherapeutics Inc. is gearing up for a second IPO attempt this year, having filed on Feb. 27 a new prospectus on the Hong Kong Stock Exchange. Two other biotechs – Genuine Biotech Ltd. and Cloudbreak Pharma Inc. – also are having another go at a listing in Hong Kong in 2025.
Genfleet Therapeutics (Shanghai) Co. Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to advance GFH-375 (VS-7375) into a phase I/II study in patients with advanced solid tumors with KRAS G12D mutation.
Genfleet Therapeutics Inc. has entered the KRAS G12C inhibitor race in the U.S. as it gears up to begin phase III trials of GFH-925 (IBI-351) in patients with refractory metastatic colorectal cancer (CRC) following FDA clearance.
Genfleet Therapeutics Inc. has entered the KRAS G12C inhibitor race in the U.S. as it gears up to begin phase III trials of GFH-925 (IBI-351) in patients with refractory metastatic colorectal cancer (CRC) following FDA clearance. GFH-925 was the first KRAS G12C inhibitor to receive breakthrough therapy designation from China's National Medical Products Administration for previously treated advanced CRC.
Verastem Inc. has announced the nomination of an oral KRAS G12D inhibitor, VS-7375 (GFH-375), as the lead program from its discovery and development collaboration with Genfleet Therapeutics (Shanghai) Inc.
Verastem Oncology Inc. and Genfleet Therapeutics Ltd. have inked a discovery and development deal to advance three oncology discovery programs targeting RAS pathway-driven cancers.
Verastem Oncology Inc. has entered into a discovery and development collaboration with Genfleet Therapeutics (Shanghai) Ltd. to advance three oncology discovery programs targeting RAS pathway-driven cancers.
Research at Genfleet Therapeutics Inc. has led to the development of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Genfleet Therapeutics (Shanghai) Inc. has patented receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of stroke, rheumatoid arthritis, psoriasis, heart failure, nonalcoholic steatohepatitis and inflammatory bowel disease.
Genfleet Therapeutics (Shanghai) Inc. has divulged pyridino- or pyrimido-cyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
